Publications Search

Publications Search

Fan W, Philip S, Toth PP, et al. Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. Am J Prevent Cardiol. 2020; epub ahead of print. https://www.sciencedirect.com/science/article/pii/S2666667720300878

Wong ND, Fan W, Philip S, et al. REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES]). Am J Cardiol. 2020; epub ahead of print.

https://www.ajconline.org/article/S0002-9149(20)30861-4/fulltext

Hilleman DE, Wiggins BS, Bottorff MB. A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review.” Adv Ther. 2020; epub ahead of print.

https://link.springer.com/article/10.1007/s12325-020-01420-z
Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial).

Nelson AJ, Navar A, Mulder H, Wojdyla D, Philip S, Granowitz C, Peterson ED, Pagidipati NJ. Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial). Am J Cardiol. 2020; epub ahead of print.

Budoff MJ, Muhlestein JB, Bhatt DL, et al. Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: A prospective, placebo-controlled randomized trial (EVAPORATE): Interim Results [published online ahead of print, 2020 Jul 1]. Cardiovasc Res. 2020;cvaa184. doi:10.1093/cvr/cvaa184

https://academic.oup.com/cardiovascres/article-abstract/doi/10.1093/cvr/cvaa184/5865857

Toth P, Granowitz C, Hull M, Philip S. Elevated triglycerides and atherosclerotic cardiovascular disease are significant predictors of major cardiovascular events and increased health care costs in statin-treated patients: a real-world analysis. J Manag Care Spec Pharm. 2018;24(4 suppl a):S70-S71.

https://www.jmcp.org/doi/pdf/10.18553/jmcp.2018.24.4-a.s1
Reductions in low-density lipoprotein cholesterol and particle concentration and improvements in other parameters of dyslipidemia in a statin-treated patient with persistent dyslipidemia and high cardiovascular risk following switch from EPA+DHA (omega-3-acid ethyl esters) to high-purity EPA (icosapent ethyl)

American Academy of Family Physician
Crandell JR. Reductions in low-density lipoprotein cholesterol and particle concentration and improvements in other parameters of dyslipidemia in a statin-treated patient with persistent dyslipidemia and high cardiovascular risk following switch from EPA+DHA (omega-3-acid ethyl esters) to high-purity EPA (icosapent ethyl). Presented at: The American Academy of Family Physicians conference

American Association of Clinical Endocrinologists
Toth P, Granowitz C, Hull M, Philip S. Elevated triglycerides (≥150 mg/dL) and diabetes mellitus are significant predictors of major cardiovascular events and increased health care costs in statin-treated patients: a real-world analysis [abstract 403]. Endocr Pract. 2018;24(suppl 1):96-97.

http://am.aace.com/files/Abstract-Book-2018.pdf

American College of Cardiology
DL, Miller M, Steg G, et al. EPA levels and cardiovascular outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Presented at the American College of Cardiology 2020 annual meeting (virtual).

https://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=062fc9e4b3a74a9fb1c196a35dad8f3b

Pisaniello AD, Nicholls SJ, Ballantyne CM, Bhatt DL, Wong ND. Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events. EMJ. 2020;5:29-36.

https://www.emjreviews.com/cardiology/symposium/eicosapentaenoic-acid-atheroprotective-properties-and-the-reduction-of-atherosclerotic-cardiovascular-disease-events/